Antimicrobial lexitropsins containing amide, amidine, and alkene linking groups

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Antimicrobial Drug Discovery

Background:

• Minor groove binders (MGBs) are DNA-interacting agents with therapeutic potential.
• Existing MGBs like distamycin and thiazotropsins serve as scaffolds for new drug design.
• Enhancing DNA binding affinity through hydrophobic interactions is a key strategy.

Purpose of the Study:

• To synthesize and characterize novel MGBs with enhanced DNA affinity.
• To evaluate the antibacterial and antifungal activities of the synthesized compounds.
• To assess the in vivo efficacy of promising candidates against bacterial infections.

Main Methods:

• Synthesis of 80 short MGBs incorporating hydrophobic aromatic head groups (quinolyl, benzoyl) and alkene linkers.
• Determination of Minimum Inhibitory Concentrations (MIC) against Staphylococcus aureus (methicillin-sensitive and -resistant strains), Aspergillus niger, and Candida albicans.
• In vivo efficacy study in mice infected with Staphylococcus aureus, administering a quinoline derivative.

Main Results:

• Several synthesized MGBs exhibited potent antibacterial activity against Staphylococcus aureus (MIC: 0.1-5 μg/mL), comparable to established drugs.
• Antifungal activity was observed against Aspergillus niger and Candida albicans (MIC: 20-50 μg/mL).
• A quinoline derivative provided protection to mice against Staphylococcus aureus infection for up to six days post-single dose.

Conclusions:

• Novel MGBs with hydrophobic modifications demonstrate significant broad-spectrum antimicrobial potential.
• The developed compounds represent promising leads for new antibacterial and antifungal therapeutics.
• In vivo data supports the therapeutic potential of specific quinoline-based MGBs in treating bacterial infections.